Results 61 to 70 of about 10,168 (235)

Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment

Cells, 2022
The success of anticancer treatments relies on a long-term response which can be mediated by the immune system. Thus, the concept of immunogenic cell death (ICD) describes the capacity of dying cancer cells, under chemotherapy or physical stress, to ...
Nicolas Roussot, François Ghiringhelli, Cédric Rébé   +2 more
doaj   +1 more source

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors

Frontiers in Oncology, 2023
BackgroundIn patients with cirrhosis, portal hypertension increases intestinal permeability, dysbiosis, and bacterial translocation, promoting an inflammatory state that can lead to the progression of liver disease and development of hepatocellular carcinoma (HCC).
Y. Linda Wu, Grace van Hyfte, Umut Özbek, Marlene Reincke, Anuhya Gampa, Yehia I. Mohamed, Naoshi Nishida, Brooke Wietharn, Suneetha Amara, Pei-Chang Lee, Bernhard Scheiner, Lorenz Balcar, Matthias Pinter, Arndt Vogel, Arndt Weinmann, Anwaar Saeed, Anjana Pillai, Lorenza Rimassa, Lorenza Rimassa, Abdul Rafeh Naqash, Mahvish Muzaffar, Yi-Hsiang Huang, Ahmed O. Kaseb, Masatoshi Kudo, David J. Pinato, Celina Ang   +25 more
openaire   +4 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models

Proceedings of the National Academy of Sciences, 2023
Immune checkpoint blockers (ICBs) have failed in all phase III glioblastoma trials. Here, we found that ICBs induce cerebral edema in some patients and mice with glioblastoma. Through single-cell RNA sequencing, intravital imaging, and CD8 + T cell blocking studies in mice, we demonstrated that this edema results ...
Datta, Meenal, Chatterjee, Sampurna, Perez, Elizabeth M., Gritsch, Simon, Roberge, Sylvie, Duquette, Mark, Chen, Ivy X., Naxerova, Kamila, Kumar, Ashwin S., Ghosh, Mitrajit, Emblem, Kyrre E., Ng, Mei R., Ho, William W., Kumar, Pragya, Krishnan, Shanmugarajan, Dong, Xinyue, Speranza, Maria C., Neagu, Martha R., Iorgulescu, J. Bryan, Huang, Raymond Y., Youssef, Gilbert, Reardon, David A., Sharpe, Arlene H., Freeman, Gordon J., Suvà, Mario L., Xu, Lei, Jain, Rakesh K.   +26 more
openaire   +2 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity

Frontiers in Oncology, 2020
The efficacy of cancer immunotherapy depends on the fine interplay between tumoral immune checkpoints and host immune system. However, the up-to-date clinical performance of checkpoint blockers in cancer therapy revealed that higher-level regulation ...
Xing Huang, Xing Huang, Xing Huang, Xiaozhen Zhang, Xiaozhen Zhang, Xiaozhen Zhang, Jian Xu, Jian Xu, Jian Xu, Xun Wang, Xun Wang, Xun Wang, Gang Zhang, Gang Zhang, Gang Zhang, Tianyu Tang, Tianyu Tang, Tianyu Tang, Xiaochao Shen, Xiaochao Shen, Xiaochao Shen, Tingbo Liang, Tingbo Liang, Tingbo Liang, Xueli Bai, Xueli Bai, Xueli Bai   +26 more
doaj   +1 more source

Novel technologies for applying immune checkpoint blockers

Cancer cells develop several ways to subdue the immune system among others via upregulation of inhibitory immune checkpoint (ICP) proteins. These ICPs paralyze immune effector cells and thereby enable unfettered tumor growth. Monoclonal antibodies (mAbs) that block ICPs can prevent immune exhaustion.
Awad, Robin Maximilian, Breckpot, Karine
openaire   +3 more sources

A Case of Acute Heart Failure due to Immune Checkpoint Blocker Nivolumab

Cardiology Research, 2019
Immune checkpoint inhibitors can be potentially cardiotoxic. It has not been frequently reported in the literature. Cardiomyopathy with these agents can have early onset and may start with non-specific symptoms like fatigue, weakness before presenting with obvious features of acute heart failure.
Sharma, Munish, Suero-Abreu, Giselle A., Kim, Bernard   +2 more
openaire   +3 more sources

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source